Global Acute Decompensated Heart Failure (ADHF) Markets 2019: Disease Background, Treatment, Epidemiology, Marketed Drugs, Pipleine, Deals, Revenues & Landscape
DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Acute Decompensated Heart Failure (ADHF)" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.
Key Takeaways
-- Approved drugs in the acute decompensated heart failure (ADHF) space
target natriuretic peptide receptors, phosphodiesterase 3, potassium
channels, and troponin-C. The majority of approved therapies are
administered via the intravenous route, with one drug also being
available in an oral formulation.
-- Therapies in active clinical development for ADHF are spread evenly
across Phase I and Phase II. Therapies in development for ADHF focus on
targets such as Na-K-Cl cotransporter, corticotropin releasing factor -
receptor2, guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum
Ca2+ -ATPase, natriuretic peptide receptors, vasopressin receptors, and
phosphodiesterase 9. These therapies are administered via the oral,
intravenous, and subcutaneous routes.
-- The overall likelihood of approval of a Phase I ADHF asset is 1.8%, and
the average probability a drug advances from Phase III is 28.6%. Drugs,
on average, take 12.9 years from Phase I to approval, compared to 9.7
years in the overall cardiovascular space.
-- There have been only two licensing and asset acquisition deals involving
ADHF drugs during 2014-19. The $2,075m acquisition of Cardioxyl by
Bristol-Myers Squibb in 2015, which also gave the company full rights to
Cardioxyl's lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug)
in Phase II clinical development as an intravenous treatment for ADHF,
was the largest deal.
-- The distribution of clinical trials across Phase I-IV indicates that the
majority of trials for ADHF have been in the early and midphases of
development, with 57% of trials in Phase I-II, and 43% in Phase III-IV.
-- The majority of industry-sponsored clinical trials have been completed.
Adrenomed has one planned trial in the ADHF space.
-- Bayer leads industry sponsors with the highest number of clinical trials
for ADHF, followed by Scios.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Definition
Symptoms
Patient subtypes
Risk factors
Diagnosis
TREATMENT
Diuretics
Vasodilator therapy
Ultrafiltration (UF)
Inotropes
Natriuretic peptides
Vasopressors/Beta blockers/ACE inhibitors
Circulatory assist devices
Other therapies
EPIDEMIOLOGY
ADHF incidence
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Entresto for ADHF (November 11, 2018)
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/u8hb5r
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
